Peer-reviewed veterinary case report
Radioiodine treatment outcomes for hyperthyroid cats with fixed
By Joana Matos et al.·Published in Open Veterinary Journal·2022·Small Animal Internal Medicine Division, Department of Clinical Veterinary Medicine, Vetsuisse Faculty University of Bern, Länggassstrasse 128, 3012 Bern, Switzerland, LY·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of radioiodine therapy for feline hyperthyroidism: Fixed dose versus individualized dose based on a clinical scoring system
- Species:
- cat
Plain-English summary
A 12-year-old cat with hyperthyroidism was treated with radioiodine therapy to help manage her condition. The study compared two methods of dosing: a fixed dose and an individualized dose based on a scoring system. Both methods resulted in similar outcomes regarding thyroid function and kidney health, with about half of the cats achieving normal thyroid levels after treatment. The average survival time for cats after treatment was around 44 months, indicating that the method of calculating the dose did not significantly affect their overall health or longevity.
People also search for: cat hyperthyroidism treatment · radioiodine therapy for cats · cat thyroid medication options
Abstract
Background: Hyperthyroidism is the most frequent endocrinopathy in older cats. To date, there is no consensus on how to best calculate the dose of radioiodine to administer to hyperthyroid cats. Aim: The goals of this study were to compare thyroid function, renal function and survival time between hyperthyroid cats receiving a fixed dose of radioiodine and those receiving an individualized dose calculated using a clinical scoring system. Methods: Medical records of 110 cats treated with radioiodine therapy at the University of Bern between 2010 and 2020 were reviewed. Thyroid function, renal function and survival of cats treated with a fixed dose of radioiodine (2010-2015; n= 50) were compared to those of cats treated with an individualized dose (2015-2020; n= 60) at different timepoints after therapy. Results: Treatment with a fixed dose of radioiodine (mean 168 ± 26 MBq) was associated with 69% of euthyroidism, 19% persistent hyperthyroidism and 12% hypothyroidism, whereas treatment with an individualized dose (mean 120 ± 30 MBq) led to 54% euthyroidism, 23% hyperthyroidism and 23% hypothyroidism (P=0.73). More than twelve months after treatment, the incidence of azotaemia was comparable between cats treated with a fixed dose (37%) and those treated with an individualized dose (31%) (P= 0.77). No factors were found to be predictive of treatment failure (hypothyroidism or hyperthyroidism) after therapy. Median survival time after radioiodine therapy was 44 months. In a multivariate analysis, persistent hyperthyroidism was the only variable independently associated with a shorter survival time (HR= 6.24, P= 0.002). Conclusion: The method of calculating the dose of radioiodine (fixed vs individualized) to treat feline hyperthyroidism does not appear to be decisive for post-treatment thyroid function, renal function or survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.5455/OVJ.2022.v12.i2.11